Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4(+) cells
在中国，巴瑞替尼的非适应症用药通过靶向CD4(+)细胞的JAK-STAT信号通路抑制MAPK和PI3K/Akt/mTOR通路，从而改善中重度特应性皮炎。
期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2024.1324892
Chen, Shuang; Li, Caihua; Tu, Zeng; Cai, Tao; Zhang, Xinying; Wang, Lei; Tian, Ruoyuan; Huang, Jinglan; Gong, Yuxuan; Yang, Xiaotong; Wu, Zetong; He, Sirong; He, Wenyan; Wang, Dan
mTOR
T细胞
JAK/STAT
信号转导
PI3K/Akt
MAPK/ERK
细胞生物学
CD4
